PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20939743-5	2010	AREAS COVERED IN THIS REVIEW: Preclinical and clinical studies of avanafil, a new oral PDE5 inhibitor being investigated for the treatment of ED.	avanafil	66-74	phosphodiesterase 5A	Homo sapiens	87-91	
20939743-8	2010	TAKE HOME MESSAGE: We propose that avanafil, which displays enhanced selectivity, faster onset of action, and a favorable side-effect profile relative to currently available PDE5 inhibitors, may offer an alternative first line treatment option for men with ED.	avanafil	35-43	phosphodiesterase 5A	Homo sapiens	174-178